Jinling Pharmaceutical (000919.SZ) subsidiary's arotinolol hydrochloride API approved for marketing.

Zhitong Finance APP News, Jinling Pharmaceutical (000919.SZ) announced that its controlling subsidiary, Chizhou Dongsheng Pharmaceutical Co., Ltd., recently received the "Chemical API Marketing Application Approval Notification" for Arotinolol Hydrochloride issued by the National Medical Products Administration. Arotinolol Hydrochloride is a receptor blocker that blocks both and receptors. Its formulation products are mainly used to treat essential hypertension (mild to moderate), angina pectoris, and other diseases.